Ensign Peak Advisors
GLUE icon

Ensign Peak Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Ensign Peak Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-240
Closed -$2K – 2325
2022
Q2 		$2K Hold
240
– – ﹤0.01% 2160
2022
Q1 		$3K Hold
240
– – ﹤0.01% 2204
2021
Q4 		$5K Buy
+240
New +$5.03K ﹤0.01% 2195

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors's GLUE Position: Q3 2022 in Review

Ensign Peak Advisors sold out of Monte Rosa Therapeutics (GLUE) in Q3 2022, closing a stake of 240 shares — an estimated $2K sold.

Ensign Peak Advisors first reported a position in GLUE in Q4 2021 and held it in 3 quarters. The position peaked at $5K in Q4 2021. 70 funds tracked by Wall St. Rank hold GLUE as of Q3 2022.

  • Ensign Peak Advisors reported no remaining Monte Rosa Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 240 Monte Rosa Therapeutics shares in Q3 2022, an estimated $2K.
  • Ensign Peak Advisors first reported a position in Monte Rosa Therapeutics in Q4 2021 and held it in 3 quarters.
  • Ensign Peak Advisors's Monte Rosa Therapeutics position peaked at $5K in Q4 2021.
  • 70 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2022.

Based on Ensign Peak Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.